Dividends & Buybacks ·
aTyr Pharma announces one-for-forty reverse stock split effective Oct. 28
ATYRaTYR PHARMA Inc
aTyr Pharma filed a Certificate of Amendment to its Restated Certificate of Incorporation with the Delaware Secretary of State to effect a one-for-forty (1-for-40) reverse stock split of its outstanding common stock. The amendment becomes effective at 5:00 p.m. Eastern Time on October 28, 2026. This action follows approval by stockholders at a Special Meeting held on October 16, 2026, and subsequent board approval on the same date. Under the terms of the split, every forty shares will be combined into one share, reducing the outstanding common stock from approximately 100.5 million to roughly 2.5 million shares. Proportionate adjustments will apply to outstanding options, warrants, and restricted stock units, while fractional shares will be rounded up to whole shares. The company's common stock is scheduled to begin trading on a split-adjusted basis under the ticker symbol ATYR on The Nasdaq Capital Market when the market opens on October 29, 2026. aTyr Pharma operates in the biotechnology industry, focusing on the development of therapies for rare diseases.